MetLife (MET) Stock Forecast & Price Target

$88.23 -0.02 (-0.02%)

(As of 11/29/2024 ET)

MetLife - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 13 Analyst Ratings

Sell
0

Hold
0

Buy
13

Based on 13 Wall Street analysts who have issued ratings for MetLife in the last 12 months, the stock has a consensus rating of "Buy." Out of the 13 analysts, 13 have given a buy rating for MET.

Consensus Price Target

$88.62
0.44% Upside

According to the 13 analysts' twelve-month price targets for MetLife, the average price target is $88.62. The highest price target for MET is $99.00, while the lowest price target for MET is $80.00. The average price target represents a forecasted upside of 0.44% from the current price of $88.23.

Get the Latest News and Ratings for MET and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for MetLife and its competitors.

MET Analyst Ratings Over Time

Type	Current Forecast 12/2/23 to 12/1/24	1 Month Ago 11/2/23 to 11/1/24	3 Months Ago 9/3/23 to 9/2/24	1 Year Ago 12/2/22 to 12/2/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	13 Buy rating(s)	13 Buy rating(s)	12 Buy rating(s)	9 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	1 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$88.62	$88.38	$83.00	$75.45
Forecasted Upside	0.44% Upside	12.69% Upside	7.12% Upside	18.34% Upside
Consensus Rating	Buy	Buy	Moderate Buy	Moderate Buy

Media Is Mocking Elon, But Wait Until They See This Demo (Ad)

Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.

Click here to watch this demo and decide for yourself.

MET Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

MET Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

MetLife Stock vs. The Competition

Type	MetLife	Finance Companies	S&P 500
Consensus Rating Score	3.00	2.49	2.50
Consensus Rating	Buy	Hold	Moderate Buy
Predicted Upside	0.44% Upside	7.97% Upside	6.52% Upside
News Sentiment Rating	Positive News See Recent MET News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/27/2024	TD Cowen 5 of 5 stars	A. Kligerman Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$97.00 ➝ $99.00	+11.50%
11/5/2024	Wells Fargo & Company 3 of 5 stars		Boost Target	Overweight ➝ Overweight	$92.00 ➝ $93.00	+18.53%
10/31/2024	Barclays 3 of 5 stars	A. Scott Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$91.00 ➝ $90.00	+14.64%
10/2/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$85.00 ➝ $92.00	+12.46%
9/27/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$89.00 ➝ $95.00	+14.71%
8/19/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$86.00 ➝ $85.00	+15.98%
Get the Latest News and Ratings for MET and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for MetLife and its competitors with MarketBeat's FREE daily newsletter.
8/1/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$99.00 ➝ $96.00	+24.92%
7/23/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$83.00 ➝ $89.00	+18.26%
7/8/2024	Keefe, Bruyette & Woods Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$86.00 ➝ $85.00	+22.30%
7/2/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$81.00 ➝ $86.00	+23.03%
5/22/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$77.00 ➝ $80.00	+9.50%
2/5/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$87.00 ➝ $82.00	+24.05%
1/8/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$70.00 ➝ $80.00	+16.08%
10/4/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Hold	$71.00	+18.33%
8/4/2023	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$70.00 ➝ $74.00	+14.14%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 07:46 AM ET.

Should I Buy MetLife Stock? MET Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, November 25, 2024. Please send any questions or comments about these MetLife pros and cons to contact@marketbeat.com.

MetLife
Bull Case

Here are some ways that investors could benefit from investing in MetLife, Inc.:

MetLife, Inc. has a strong consensus rating of "Buy" from fourteen analysts, indicating positive market sentiment and potential for price appreciation.
The stock is currently trading at $82.60, which is below the average target price of $88.46, suggesting a potential upside for investors.
Recent analyst upgrades have set target prices as high as $97.00, reflecting confidence in the company's growth prospects and financial health.
MetLife, Inc. offers a quarterly dividend of $0.545 per share, translating to an annualized dividend yield of approximately 2.64%, providing income to investors.
The company has a solid market capitalization of $57.19 billion, indicating stability and the ability to invest in growth opportunities.

MetLife
Bear Case

Investors should be bearish about investing in MetLife, Inc. for these reasons:

The current ratio and quick ratio are both at 0.16, suggesting potential liquidity issues, which could impact the company's ability to meet short-term obligations.
MetLife, Inc. has a debt-to-equity ratio of 0.51, indicating a moderate level of debt that could pose risks if interest rates rise or if the company faces financial challenges.
Despite a strong market position, the stock has experienced fluctuations, with a 12-month low of $62.14, which may concern risk-averse investors.
Market volatility, as indicated by a beta of 1.05, suggests that the stock may be more sensitive to market movements, which could lead to increased risk for investors.
Analysts have varying target prices, with some as low as $85.00, indicating uncertainty about the stock's future performance.

MET Forecast - Frequently Asked Questions

: According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for MetLife is $88.62, with a high forecast of $99.00 and a low forecast of $80.00.
: 13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MetLife in the last year. There are currently 13 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MET shares.
: According to analysts, MetLife's stock has a predicted upside of 0.44% based on their 12-month stock forecasts.
: MetLife has been rated by research analysts at Barclays, Jefferies Financial Group, Piper Sandler, TD Cowen, and Wells Fargo & Company in the past 90 days.
: Analysts like MetLife more than other "finance" companies. The consensus rating for MetLife is Buy while the average consensus rating for "finance" companies is Hold. Learn more on how MET compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

The indicator behind Nvidia’s rally has a new prospect (Ad)

Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…

All you have to do is follow this link here

This page (NYSE:MET) was last updated on 12/1/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MetLife (MET) Stock Forecast & Price Target